KITE PHARMA, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
Clinical Trials
64
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)β’ Click on a phase to view related trials
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
- Conditions
- Systemic Lupus ErythematosusLupus NephritisSystemic SclerosisIdiopathic Inflammatory Myopathy
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 52
- Registration Number
- NCT07038447
- Locations
- π¦πΊ
Concord Repatriation General Hospital, Syndey, New South Wales, Australia
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-11-12
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- πΊπΈ
University of Illinois Hospital and Health Sciences System, Chicago, Illinois, United States
πΊπΈWeill Cornell Medicine - New York Presbyterian Hosptial, New York, New York, United States
π¨πΏFakultni Nemocnice Ostrava, Severomoravsky KRAJ, Czechia
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 25
- Registration Number
- NCT06253663
- Locations
- π―π΅
Chiba University Hospital, Chiba, Japan
π―π΅Kyushu University Hospital, Fukuoka, Japan
π―π΅Hokkaido University Hospital, Hokkaido, Japan
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- πΊπΈ
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
πΊπΈUniversity of Chicago Medical Center, Chicago, Illinois, United States
πΊπΈHenry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Conditions
- Large B-cell LymphomaFollicular Lymphoma
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-10-27
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776160
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈUniversity of Texas Southwestern Medical Center, Dallas, Texas, United States
πΊπΈUniversity of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility
A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility.